Physician profile
Vikas Verma
NPI 1528082468
$8,303.79
in general payments reported to CMS, 2019-2025
39 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $823 · 2020: $351 · 2021: $263 · 2022: $901 · 2023: $3,442 · 2024: $1,387 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,855 · Travel and Lodging: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,855.35 |
| Travel and Lodging | $1,111.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $1,739.93 | 2023-2025 | Remede System |
| Cvrx, INC. | $1,182.23 | 2022-2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $609.39 | 2019-2025 | |
| Atricure, INC. | $502.19 | 2022-2025 | Synergy Ablation System, Atriclip Laa Exclusion System, Epi-Ease Epicardial Access System |
| Amgen INC. | $427.38 | 2019-2025 | Repatha, Repatha |
| Kestra Medical Technology Services, INC. | $427.22 | 2022-2023 | Assure Wcd |
| Medtronic, INC. | $362.39 | 2023-2024 | Venaseal |
| Pfizer INC. | $346.40 | 2019-2025 | |
| Impulse Dynamics (USA) INC. | $312.03 | 2022-2023 | Optimizer |
| Boston Scientific Corporation | $196.37 | 2019-2023 | Ekosonic |
| Abiomed | $195.38 | 2022-2025 | Impella |
| E.R. Squibb & Sons, L.L.C. | $190.12 | 2019-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $188.34 | 2020-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $155.71 | 2019-2023 | Xarelto |
| Actelion Pharmaceuticals US, INC. | $152.03 | 2025 | Uptravi, Opsumit |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vikas Verma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.